Company Name, Ticker, Industry, else..

Tvardi Therapeutics Inc (NASDAQ: TVRD)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Tvardi Therapeutics Inc 's

Name: Tvardi Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TVRD Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Tvardi Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 9 %, recorded in the same quarter.

• List of TVRD Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Tvardi Therapeutics Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< TVRD Stock Performance Comparisons

Tvardi Therapeutics Inc 's Comment on Competition and Industry Peers

The company operates in a competitive environment alongside other biopharmaceutical and biotechnology firms developing treatments for inflammatory and proliferative diseases. Competitors developing STAT3 inhibitors include Moleculin Biotech, Purple Biotech, and Scopus BioPharma. In the treatment of idiopathic pulmonary fibrosis (IPF), approved products include nerandomilast (JASCAYD) and nintedanib (Ofev), both from Boehringer Ingelheim Pharma GmbH & Co. KG, as well as pirfenidone (Esbriet), marketed by Roche Holding AG. The company recognizes that its patents may be subject to challenges or circumvention and that trade secrets may not fully safeguard its competitive position.

<< See the full list of TVRD competitors

*Market share is calculated based on total revenue.

TVRD's Stock Performance relative to its Competitors

Publicly Traded Peers of Tvardi Therapeutics Inc

Indivior Pharmaceuticals Inc
Share Performance

-7.70%

This Quarter

Indivior Pharmaceuticals Inc

Profile

The company develops, markets, and sells pharmaceutical products.

More about Indivior Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4,451.790 mill.	$ 1,292.000 mill.	$ 252.000 mill.

Gb Sciences Inc
Share Performance

0.00%

Over The Past 5 Days

Gb Sciences Inc

Profile

Gb Sciences Inc uses a business model that focuses on the development of plant-based medicine and therapies using their proprietary growing techniques and advanced research and development capabilities. They aim to leverage their expertise in plant genetics, cultivation, and extraction to create innovative and effective solutions for the medical industry while pursuing strategic partnerships and licensing opportunities.

More about Gb Sciences Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.122 mill.	$ 0.097 mill.	$ -1.043 mill.

Evoke Pharma Inc
Share Performance

+139.65%

One Year

Evoke Pharma Inc

Profile

Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.

More about Evoke Pharma Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 28.131 mill.	$ 14.425 mill.	$ -5.226 mill.

Enveric Biosciences Inc
Share Performance

-16.57%

This Quarter

Enveric Biosciences Inc

Profile

Enveric Biosciences Inc's business model centers around the development and commercialization of innovative cannabinoid medicines and therapies to address various medical conditions, primarily focusing on cancer-related symptoms and improving patient outcomes. The company aims to leverage its expertise in the pharmaceutical industry to advance its pipeline, obtain regulatory approvals, and establish strategic partnerships for the distribution and sale of its products.

More about Enveric Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 5.821 mill.	$ - mill.	$ -8.729 mill.

Canton Strategic Holdings Inc
Share Performance

-18.87%

This Quarter

Canton Strategic Holdings Inc

Profile

The company is transitioning from biotechnology to a digital asset treasury strategy focused on Canton Coin.

More about Canton Strategic Holdings Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 466.260 mill.	$ 1.496 mill.	$ -68.700 mill.

18 more competitors available

Sources: Tvardi Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 10, 2026 1:47 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tvardi Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.